|Tested species reactivity||Human|
|Published species reactivity||Rabbit, Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Purified recombinant fragment of human CD105 expressed in E. Coli.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:200 - 1:400|
|Immunocytochemistry (ICC)||1:200 - 1:1000|
|Immunofluorescence (IF)||1:200 - 1:1000|
|Immunohistochemistry (IHC)||1:200 - 1:1000|
|Western Blot (WB)||1:500 - 1:2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-17041 targets CD105 in FACS, ICC, IF, IHC, and WB applications and shows reactivity with Human samples.
The MA5-17041 immunogen is purified recombinant fragment of human CD105 expressed in E. Coli.
MA5-17041 detects CD105 which has a predicted molecular weight of approximately 71kDa.
This gene encodes a homodimeric transmembrane protein which is a major glycoprotein of the vascular endothelium. This protein is a component of the transforming growth factor beta receptor complex and it binds TGFB1 and TGFB3 with high affinity. Mutations in this gene cause hereditary hemorrhagic telangiectasia, also known as Osler-Rendu-Weber syndrome 1, an autosomal dominant multisystemic vascular dysplasia.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
A study to identify and characterize the stem/progenitor cell in rabbit meniscus.
MA5-17041 was used in western blot to examine the role of meniscus-derived stromal cells in healing
|Huang H,Wang S,Gui J,Shen H||Cytotechnology (68:2083)||2016|
Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.
MA5-17041 was used in immunohistochemistry to study the value of CD105, VEGF and sFLT1 in predicting the presence of metastases in endometrioid endometrial carcinoma
|Saarelainen SK,Staff S,Peltonen N,Lehtimäki T,Isola J,Kujala PM,Vuento MH,Mäenpää JU||Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (35:4651)||2014|